Skip to main content

Table 2 Fulfilled all the criteria for prescribing omalizumab at baseline vs response

From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

 

Response

  

Yes

No

Total

Criteria fulfilled yes

173

87

260

Criteria fulfilled no

91

52

143

Total

264

139

403

 

p = 0.558

  
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us